Insight Molecular Diagnostics (IMDX) Non-Current Assets (2015 - 2026)

Insight Molecular Diagnostics has disclosed Non-Current Assets across 12 years of filings, most recently posting $8.9 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $8.9 million, up 24.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.9 million (up 24.54% YoY), and the FY2025 annual result was $9.2 million, up 46.27% from the prior year.
• Non-Current Assets came in at $8.9 million for Q1 2026 at Insight Molecular Diagnostics, down from $9.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $121.7 million in Q2 2022 to a low of $5.4 million in Q4 2023.
• The 5-year median for Non-Current Assets is $64.7 million (2023), against an average of $51.9 million.
• Across the five-year window, Non-Current Assets jumped 82.98% in 2022 and sank 92.71% in 2023, its largest moves.
• Insight Molecular Diagnostics' Non-Current Assets stood at $74.6 million in 2022, then tumbled by 92.71% to $5.4 million in 2023, then grew by 16.34% to $6.3 million in 2024, then surged by 46.27% to $9.2 million in 2025, then dropped by 3.66% to $8.9 million in 2026.
• The last three Non-Current Assets figures came in at $8.9 million (Q1 2026), $9.2 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.